| Assessment Status | Assessment Process Complete |
| HTA ID | 21002 |
| Drug | Pembrolizumab |
| Brand | Keytruda® |
| Indication | Is indicated as monotherapy for the first-line treatment of adult patients with metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer in adults. |
| Assessment Process | |
| Rapid review commissioned | 08/02/2021 |
| Rapid review completed | 03/03/2021 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of pembrolizumab compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 24/03/2021 |
| Pre-submission consultation with Applicant | 21/04/2021 |
| Full submission received from Applicant | 21/01/2022 |
| Preliminary review sent to Applicant | 10/06/2022 |
| NCPE assessment re-commenced | 08/07/2022 |
| Factual accuracy sent to applicant | 07/09/2022 |
| NCPE assessment re-commenced | 19/09/2022 |
| NCPE assessment completed | 13/10/2022 |
| NCPE assessment outcome | The NCPE recommends that pembrolizumab be considered for reimbursement if cost effectiveness can be improved relative to existing treatments*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013
